Liver Cancer Diagnostics Market Forecast to 2028

ReportLinker

The liver cancer diagnostics market size is expected to reach US$15,951. 77 million by 2028 from $9,323. 14 million in 2021; it is estimated to grow at a CAGR of 8.0% between 2021 and 2028.

New York, April 21, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the publication of the report “Liver Cancer Diagnostics Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Type and End User” – https://www.reportlinker.com/p06270016/?utm_source=GNW
The report highlights the key factors driving the market and prominent players in their developments. The growth of the liver cancer diagnostics market is mainly attributed to the increasing prevalence of liver cancer and increasing R&D investments in the development of new diagnostic tests.

On the other hand, the high cost of technologically advanced liver cancer diagnostic solutions is hampering the market growth.

Hepatocellular carcinoma is the most common type of liver; it starts in the main type of liver cell (hepatocyte) and is the most common type of primary liver cancer. Hepatocellular carcinoma most often occurs in people with chronic liver disease, such as cirrhosis caused by hepatitis B or hepatitis C.

Additionally, other types of liver cancer are much less common, such as intrahepatic cholangiocarcinoma and hepatoblastoma. Cancer that starts in another area of ​​the body, such as the colon, lung, or breast, and then spreads to the liver is called metastatic cancer.

Also, metastatic colon cancer is a type of cancer that starts in the colon and spreads to the liver. cancer and approximately 18,600 men and 9,000 women die from it.

The percentage of Americans who have liver cancer has been increasing for several decades. Liver cancer is more common in other parts of the world than in the United States. Moreover, according to an article published in CCO (Chinese Clinical Oncology), hepatocellular cancer (HCC) is one of the leading causes of cancer death worldwide. In Europe, HCC is responsible for approximately 47,000 deaths per year. The incidence is relatively low except in southern Europe, where the age-standardized incidence rate in men is 9.8 per 100,000 compared to 3.8 in northern Europe, 4.6 in central Europe and Eastern and 7.2 in Western Europe. However, in the UK, HCC death rates are expected to increase by 14% between 2006 and 2025, representing the largest increase of any male cancer. Additionally, being overweight or obese is a risk factor for liver cancer and non-alcoholic fatty liver disease is a common condition in obese people. People with a subtype of nonalcoholic fatty liver disease, known as nonalcoholic steatohepatitis (NASH), can develop cirrhosis, which can cause liver cancer. According to a research article by Eunsun Kim et al., published in Experimental & Molecular Medicine Journal 2020, the incidence rate associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing, and the The global burden of mortality from hepatocellular carcinoma (HCC) is expected to reach 1 million deaths per year by 2030. In addition, some inherited metabolic diseases can lead to cirrhosis. Lifestyle and behaviors such as smoking cigarettes and drinking alcohol are the leading cause of cirrhosis in the United States, which is linked to an increased risk of liver cancer. Additionally, type 2 diabetes has been associated with an increased risk of liver cancer, usually in patients with other risk factors such as heavy alcohol consumption or chronic viral hepatitis. This risk may also be increased because people with type 2 diabetes tend to be overweight or obese, which, in turn, can cause liver problems. According to the tenth edition 2021 of the IDF Diabetes Atlas, approximately 537 million adults (20-79 years old) are living with diabetes. The total number of people with diabetes is expected to reach 643 million by 2030 and 783 million by 2045. The factors mentioned above increase the risks of liver cancer, thereby boosting the liver cancer diagnostics market.

The global liver cancer diagnostics market, based on type, is segmented into laboratory tests, endoscopy, imaging, biopsy and others. The laboratory testing segment market is further segmented into blood tests and biomarkers.

The laboratory testing segment held the largest market share in 2021. However, the imaging segment is expected to register a CAGR of 8.5% in the market during the forecast period. On the basis of end-user, the global liver cancer diagnostics market is segmented into hospitals and diagnostic laboratories, academic and research institutes, and CRO laboratories. The hospital and diagnostic laboratory segment held the largest market share in 2021, as hospitals provide healthcare facilities with specialized scientific equipment. A team of qualified personnel is in charge of treating, investigating and solving problems associated with modern medical science in the hospital. Various medical research teams are constantly working on the introduction of innovative technologies related to diagnostic methods and other activities in the medical field. Patients generally prefer the hospital to undergo treatment for liver cancer due to the availability of advanced treatment options. Hospitals are the place of care for patients. Moreover, the same segment is expected to register a CAGR of 8.5% in the market during the forecast period.

Some of the major primary as well as secondary sources mentioned while preparing the Liver Cancer Diagnostics market report are National Center for Health Statistics; Centers for Disease Control and Prevention (CDC); National Institute of Statistics, Geography and Informatics; National Council for Health and Medical Research; and World Health Organization.
Read the full report: https://www.reportlinker.com/p06270016/?utm_source=GNW

On Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Comments are closed.